FDA Authorizes Robotic System for En Bloc Bladder Resection

By HospiMedica International staff writers
Posted on 16 Nov 2026

Bladder cancer frequently recurs, making accurate staging essential for treatment planning. Conventional transurethral resection can fragment tumors, complicating margin assessment and detrusor muscle sampling needed for pathological evaluation. A new system aims to improve specimen quality by enabling removal of bladder lesions in one piece, preserving intact tissue that includes detrusor muscle.

The U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the Virtuoso Endoscopy System, establishing it as the first device in a new classification of electromechanical surgical systems for endoluminal procedures. The system is designed for transurethral en bloc resection of bladder lesions in adult patients to obtain tissue samples, including detrusor muscle, for diagnostic evaluation of bladder cancer. The platform enables removal of many tumors in one piece or larger segments, preserving tissue architecture for pathological review and staging.


Image: The FDA granted De Novo authorization to the Virtuoso Endoscopy System for en bloc resection of bladder lesions to obtain tissue, including detrusor muscle, for diagnostic evaluation (Photo courtesy of Virtuoso Surgical)

The system operates by placing two needle-sized robotic arms at the tip of a rigid endoscope. Constructed from superelastic concentric nitinol tubes, the arms translate the surgeon’s hand motions from a console to lift, retract, and dissect beneath the lesion, providing two-handed dexterity for endoscopic surgery through the urethra. This approach is intended to support intact tissue acquisition and margin evaluation during transurethral procedures.

The FDA authorization establishes a new device classification for robotic instruments passed through an endoscope into the body. The Virtuoso Endoscopy System also received Breakthrough Device Designation in September 2025. Its authorized indications are limited to bladder procedures where a transurethral approach is appropriate, while all other uses remain investigational and are not FDA-authorized.

Clinical evidence from the initial 20 patients in the Virtuoso-sponsored VIABLE (Virtuoso Improving Anatomic Bladder Lesion Excision) study, all treated at The Chinese University of Hong Kong, showed detrusor muscle present in 94% of removed lesions. This exceeded the study’s 60% performance goal and the approximately 70% median rate reported across published studies of conventional transurethral resection of bladder tumors (systematic literature review, data on file). Surgical margins were evaluable in 93% of malignant lesions, and no intraoperative adverse events were reported.

“This is a major milestone for our team and for patients with bladder cancer. Removing a tumor intact can provide a better tissue specimen, which supports clearer diagnosis and staging. We are excited to give surgeons a new tool for this common, recurrent, and potentially deadly cancer,” said Duke Herrell, M.D., urologic surgeon and CEO of Virtuoso Surgical.

“Robotic en bloc resection with Virtuoso changed how we approach these tumors, even for surgeons experienced in the conventional en bloc technique. Surgeons newer to en bloc techniques also obtained high-quality specimens, which could help bring this approach to patients everywhere,” said Professor Jeremy Teoh, principal investigator for VIABLE at The Chinese University of Hong Kong.

Related Links
Virtuoso Surgical


Latest Surgical Techniques News